CATHERINE MOUZIN: Open Payments
NPI 1073587341 · VINCENNES, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$598 in 36 payments from 20 companies in 2025. Trend: 2023 $439 · 2024 $474 · 2025 $598
Food & beverage: $598
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $83 |
| Amgen Inc. | 4 | $68 |
| Lilly USA, LLC | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| GlaxoSmithKline, LLC. | 3 | $45 |
| Novo Nordisk Inc | 2 | $43 |
| Lundbeck LLC | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Ardelyx, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: Kerendia, REXULTI, Ozempic, EVENITY, MOUNJARO, GEMTESA, JARDIANCE, SHINGRIX.
Industry payments across IN — which companies pay providers there.
